Recently, Green Leaf Pharmaceutical announced that its product, Xuezhikang Capsule (hereinafter referred to as Xuezhikang), was approved for marketing in Uzbekistan for the auxiliary treatment of hyperlipidemia and cardio cerebral Vascular disease caused by hyperlipidemia and Atherosclerosis. It is reported that Xuezhikang is a pure natural lipid-lowering drug made from special red koji fermented by modern GMP production process. It has been on the market for more than 20 years. As one of the first choice drugs for patients with Dyslipidemia, it was recommended by the Chinese Guidelines for Lipid Management (2023) and included in the latest version of the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog and the National Essential medicines Catalog. In recent years, Green Leaf Pharmaceutical has been actively promoting the "modernization" and "internationalization" of Xuezhikang. The approval of Xuezhikang in Uzbekistan is of great significance for building the "Healthy Silk Road". Liu Dianbo, Chairman of the Board of Directors of Green Leaf Life Sciences Group, stated: "As a Chinese pharmaceutical enterprise focusing on innovation and internationalization, the approval of Xuezhikang in Uzbekistan is just a starting point. In the future, we hope to work together to accelerate the improvement of the level of local Drug development in Uzbekistan, so that high-quality Chinese innovative drugs can quickly enter the local market of Uzbekistan, and better meet the drug needs of the people of Uzbekistan and medical institutions."